{"id":"topiramate-propranolol","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Dizziness"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Drowsiness"}]},"_chembl":{"chemblId":"CHEMBL1671","moleculeType":"Small molecule","molecularWeight":"295.81"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Topiramate's mechanism of action is complex and multifaceted, involving the blockade of voltage-dependent sodium channels, which reduces the frequency of action potentials in neurons. Additionally, topiramate enhances the activity of GABA at the GABA_A receptor, which is the primary inhibitory neurotransmitter in the brain. This dual mechanism of action contributes to its anticonvulsant and neuroprotective effects.","oneSentence":"Topiramate is an anticonvulsant that blocks voltage-dependent sodium channels and enhances the activity of GABA at the GABA_A receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:26.496Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seizure prevention in patients with epilepsy"},{"name":"Migraine prevention"}]},"trialDetails":[{"nctId":"NCT06972056","phase":"PHASE4","title":"Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-07-09","conditions":"Migraine","enrollment":1335},{"nctId":"NCT03461874","phase":"NA","title":"ACT Therapy for HF Migraine","status":"COMPLETED","sponsor":"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta","startDate":"2018-03-15","conditions":"Migraine Without Aura","enrollment":64},{"nctId":"NCT07203248","phase":"","title":"Chinese Real-world Study of Treatment of Vestibular Migraine","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-12","conditions":"Vestibular Migraine, Dizziness, Vertigo","enrollment":2000},{"nctId":"NCT02670161","phase":"PHASE4","title":"Quality Improvement and Practice Based Research in Neurology Using the EMR","status":"ENROLLING_BY_INVITATION","sponsor":"Endeavor Health","startDate":"2016-05","conditions":"Brain Tumors, Epilepsy, Migraine","enrollment":3300},{"nctId":"NCT01950520","phase":"PHASE2","title":"Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2014-02-07","conditions":"Healthy Volunteers","enrollment":47},{"nctId":"NCT06499116","phase":"PHASE4","title":"Comparison of the Effectiveness of First-line Preventive Treatment of Migraine in Primary Care","status":"NOT_YET_RECRUITING","sponsor":"Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina","startDate":"2024-10","conditions":"Migraine","enrollment":460},{"nctId":"NCT00777218","phase":"NA","title":"Cognitive Side Effects of Commonly Prescribed Medications in Pediatric Migraine","status":"WITHDRAWN","sponsor":"University of South Alabama","startDate":"2007-08","conditions":"Migraine","enrollment":""},{"nctId":"NCT01060111","phase":"PHASE4","title":"An Efficacy and Tolerability Study of Topiramate in Participants With Migraine","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2006-07","conditions":"Migraine","enrollment":250},{"nctId":"NCT00862095","phase":"PHASE4","title":"Medical Therapies for Chronic Post-Traumatic Headaches","status":"TERMINATED","sponsor":"Madigan Army Medical Center","startDate":"2008-06","conditions":"Headache","enrollment":64},{"nctId":"NCT00772031","phase":"PHASE3","title":"NINDS CRC Chronic Migraine Treatment Trial","status":"COMPLETED","sponsor":"Anne Lindblad","startDate":"2008-10","conditions":"Chronic Migraine","enrollment":191},{"nctId":"NCT00236561","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Two Doses of Topiramate Compared to Placebo and Propranolol in the Prevention of Migraine","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2001-04","conditions":"Migraine, Common Migraine, Classic Migraine","enrollment":786}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":214,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"topiramate, propranolol","genericName":"topiramate, propranolol","companyName":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","companyId":"johnson-johnson-pharmaceutical-research-development-l-l-c","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Topiramate is an anticonvulsant that blocks voltage-dependent sodium channels and enhances the activity of GABA at the GABA_A receptor. Used for Seizure prevention in patients with epilepsy, Migraine prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}